A role for IL-1 inhibitors in the treatment of non-alcoholic fatty liver disease (NAFLD)?
Open accessAbstract
Interleukin-1 (IL-1) was one of the first characterized cytokines with a receptor repertoire in most organs of the human body [1]. IL-1 type cytokines and IL-1 receptor (IL-1R) members have grown r...
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Deficiency of IL-33 did not affect NASH-induced fibrosis.
“However, deficiency of IL-33 did not affect NASH-induced fibrosis.89”
From Understanding the cellular interactome of non-alcoholic fatty liver disease (2022) · cites this paper as [89]
Together these data suggest complex roles for IL-33 and ILC-2 in NASH and possibly thresholds for IL-33 that need to be surpassed to modulate fibrosis.
“Together, these data suggest complex roles for IL-33 and ILC-2 in NASH and possibly thresholds for IL-33 that need to be surpassed to modulate fibrosis.”
From Understanding the cellular interactome of non-alcoholic fatty liver disease (2022) · cites this paper as [89]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482 · see citing works
The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance
Vandanmagsar, B., Youm, Y.-H., Ravussin, A., Galgani, J. E., Stadler, K., Mynatt, R. L., Ravussin, E., Stephens, J. M., & Dixit, V. D. (2011) · Nature Medicine · doi:10.1038/nm.2279 · Cited by 2,655 · see citing works
Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
Tilg, H., & Moschen, A. R. (2010) · Hepatology · doi:10.1002/hep.24001 · Cited by 2,548 · see citing works
Self-citationInterleukin-1-receptor antagonist in type 2 diabetes mellitus
Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065213 · Cited by 1,798 · see citing works
Hoffman, H. M., Mueller, J. L., Broide, D. H., Wanderer, A. A., & Kolodner, R. D. (2001) · Nature Genetics · doi:10.1038/ng756 · Cited by 1,679 · see citing works
Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis
Diehl, A. M., & Day, C. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1503519 · Cited by 1,283 · see citing works
NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice
Mridha, A. R., Wree, A., Robertson, A. A. B., Yeh, M. M., Johnson, C. D., Van Rooyen, D. M., Haczeyni, F., Teoh, N. C.-H., Savard, C., Ioannou, G. N., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.01.022 · Cited by 1,110 · see citing works
The intestinal microbiota fuelling metabolic inflammation
Tilg, H., Zmora, N., Adolph, T. E., & Elinav, E. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0198-4 · Cited by 1,089 · see citing works
Self-citationInterleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity
Mantovani, A., Dinarello, C. A., Molgora, M., & Garlanda, C. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.012 · Cited by 1,046 · see citing works
A guiding map for inflammation
Netea, M. G., Balkwill, F., Chonchol, M., Cominelli, F., Donath, M. Y., Giamarellos-Bourboulis, E. J., Golenbock, D., Gresnigt, M. S., Heneka, M. T., Hoffman, H. M., et al. (2017) · Nature Immunology · doi:10.1038/ni.3790 · Cited by 831 · see citing works
Self-citationStienstra, R., Joosten, L. A. B., Koenen, T. B., van Tits, B. L. J. H., van Diepen, J. A., van den Berg, S. A. A., Rensen, P. C. N., Voshol, P. J., Fantuzzi, G., Hijmans, A., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.11.011 · Cited by 681 · see citing works
Dror, E., Dalmas, É., Meier, D. T., Wueest, S., Thévenet, J., Thienel, C., Timper, K., Nordmann, T. M., Traub, S., Schulze, F., et al. (2017) · Nature Immunology · doi:10.1038/ni.3659 · Cited by 396 · see citing works
Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes
Everett, B. M., Donath, M. Y., Pradhan, A. D., Thuren, T. Y., Pais, P. S., Nicolau, J. C., Glynn, R. J., Libby, P., & Ridker, P. M. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.03.002 · Cited by 328 · see citing works
Tilg, H., Moschen, A. R., & Szabó, G. (2016) · Hepatology · doi:10.1002/hep.28456 · Cited by 319 · see citing works
Self-citationKamari, Y., Shaish, A., Vax, E., Shemesh, S. S., Kandel-Kfir, M., Arbel, Y., Olteanu, S., Barshack, I., Dotan, S., Voronov, E., et al. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.01.048 · Cited by 288 · see citing works
IL-37 protects against obesity-induced inflammation and insulin resistance
Ballak, D. B., van Diepen, J. A., Moschen, A. R., Jansen, H. J., Hijmans, A., Groenhof, G.-J., Leenders, F., Bufler, P., Boekschoten, M. V., Müller, M. M., et al. (2014) · Nature Communications · doi:10.1038/ncomms5711 · Cited by 221 · see citing works
Self-citationCaspase-1 as a Central Regulator of High Fat Diet-Induced Non-Alcoholic Steatohepatitis
Dixon, L. J., Flask, C. A., Papouchado, B. G., Feldstein, A. E., & Nagy, L. E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056100 · Cited by 188 · see citing works
Moschen, A. R., Molnar, C., Enrich, B., Geiger, S., Ebenbichler, C. F., & Tilg, H. (2011) · Molecular Medicine · doi:10.2119/molmed.2010.00108 · Cited by 185 · see citing works
Self-citationHe, J., Usui, I., Ishizuka, K., Kanatani, Y., Hiratani, K., Iwata, M., Bukhari, A., Haruta, T., Sasaoka, T., & Kobayashi, M. (2005) · Molecular Endocrinology · doi:10.1210/me.2005-0107 · Cited by 109 · see citing works
Pihlajamäki, J., Kuulasmaa, T., Kamińska, D., Simonen, M., Kärjä, V. J., Grönlund, S., Käkelä, P., Pääkkönen, M. E., Kainulainen, S., Punnonen, K. R. A., et al. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.10.005 · Cited by 107 · see citing works
Cai, C., Zhu, X.-W., Li, P.-Z., Li, J., Gong, J.-P., Shen, W., & He, K. (2017) · Inflammation · doi:10.1007/s10753-017-0628-z · Cited by 83 · see citing works
Højen, J. F., Kristensen, M. L. V., McKee, A. S., Wade, M. T., Azam, T., Lunding, L. P., de Graaf, D. M., Swartzwelter, B. J., Wegmann, M., Tolstrup, M., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0467-1 · Cited by 80 · see citing works
IL-33 treatment attenuated diet-induced hepatic steatosis but aggravated hepatic fibrosis
Gao, Y., Liu, Y., Yang, M., Guo, X., Zhang, M., Li, H., Li, J., & Zhao, J. (2016) · Oncotarget · doi:10.18632/oncotarget.9259 · Cited by 79 · see citing works
Cazanave, S., Podtelezhnikov, A., Jensen, K., Seneshaw, M., Kumar, D. P., Min, H.-K., Santhekadur, P. K., Banini, B., Mauro, A. G., M. Oseini, A., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17370-6 · Cited by 66 · see citing works
Yamanishi, K., Maeda, S., Kuwahara‐Otani, S., Watanabe, Y., Yoshida, M., Ikubo, K., Okuzaki, D., El‐Darawish, Y., Li, W., Nakasho, K., et al. (2016) · Translational research · doi:10.1016/j.trsl.2016.03.010 · Cited by 47 · see citing works
Endogenous IL-33 has no effect on the progression of fibrosis during experimental steatohepatitis
Vasseur, P., Dion, S., Filliol, A. A., Genêt, V., Lucas‐Clerc, C., Girard, J., Silvain, C., Lecron, J., Piquet‐Pellorce, C., & Samson, M. (2017) · Oncotarget · doi:10.18632/oncotarget.18335 · Cited by 24 · see citing works
Administration of IL-1ra improves adiponectin levels in chronic hemodialysis patients
Hung, A. M., Limkunakul, C., Placido, J. S., Siew, E. D., Ellis, C. D., Shintani, A., & Ikizler, T. A. (2014) · Journal of Nephrology · doi:10.1007/s40620-014-0070-3 · Cited by 15 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Understanding the cellular interactome of non-alcoholic fatty liver disease
Wallace, S. J., Tacke, F., Schwabe, R. F., & Henderson, N. C. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100524 · Cited by 116 · see citing works
Ghanbari, M., Maragheh, S. M., Aghazadeh, A., Mehrjuyan, S. R., Hussen, B. M., Shadbad, M. A., Dastmalchi, N., & Safaralizadeh, R. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107765 · Cited by 99 · see citing works
Interleukins: Pathogenesis in Non-Alcoholic Fatty Liver Disease
Rafaqat, S., Gluščević, S. V., Mercantepe, F., Rafaqat, S., & Klisic, A. N. (2024) · Metabolites · doi:10.3390/metabo14030153 · Cited by 77 · see citing works
TLR9 in MAFLD and NASH: At the Intersection of Inflammation and Metabolism
Shepard, C. R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.613639 · Cited by 58 · see citing works
Meyer, M., Schwärzler, J., Jukic, A., & Tilg, H. (2024) · Biomolecules · doi:10.3390/biom14040476 · Cited by 50 · see citing works
Self-citationZhao, M., Chen, S., Ji, X., Shen, X., You, J., Liang, X., Yin, H., & Zhao, L. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105517 · Cited by 47 · see citing works
Inflammation and Fibrogenesis in MAFLD: Role of the Hepatic Immune System
Torre, P., Motta, B., Sciorio, R., Masarone, M., & Persico, M. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.781567 · Cited by 41 · see citing works
Does Resveratrol Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)?
Kasprzak‐Drozd, K., Niziński, P., Kasprzak, P., Kondracka, A., Oniszczuk, T., Rusinek, A., & Oniszczuk, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073746 · Cited by 37 · see citing works
Development of Thyroid Hormones and Synthetic Thyromimetics in Non-Alcoholic Fatty Liver Disease
Zhao, M., Xie, H., Shan, H., Zheng, Z., Li, G., Li, M., & Hong, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031102 · Cited by 32 · see citing works
Ziółkiewicz, A., Niziński, P., Soja, J., Oniszczuk, T., Combrzyński, M., Kondracka, A., & Oniszczuk, A. (2024) · Metabolites · doi:10.3390/metabo14060346 · Cited by 21 · see citing works
Kucsera, D., Tóth, V. É., Gergő, D., Vörös, I., Onódi, Z., Görbe, A., Ferdinandy, P., & Varga, Z. V. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.609465 · Cited by 19 · see citing works
Transcriptome changes in stages of non-alcoholic fatty liver disease
Aljabban, J., Rohr, M., Syed, S. A., Khorfan, K., Borkowski, V. J., Aljabban, H., Segal, M., Mukhtar, M., Mohammed, M., Panahiazar, M., et al. (2022) · World Journal of Hepatology · doi:10.4254/wjh.v14.i7.1382 · Cited by 18 · see citing works
Barbhuiya, P. A., Ahmed, A., Dutta, P. P., Sen, S., & Pathak, M. P. (2025) · Current Nutrition Reports · doi:10.1007/s13668-024-00598-w · Cited by 17 · see citing works
Recent Progress in the Molecular Imaging of Nonalcoholic Fatty Liver Disease
Wegrzyniak, O., Rosestedt, M., & Eriksson, O. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147348 · Cited by 17 · see citing works
Targeting Metabolism: Innovative Therapies for MASLD Unveiled
Wang, W., Gao, X., Niu, W., Yin, J., & He, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094077 · Cited by 14 · see citing works
The pivotal role of cytokines in liver disease pathogenesis and therapeutic potential
Li, L., Li, X., & Zhang, F. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1694582 · Cited by 11 · see citing works
Simeone, P., Costantino, S., Liani, R., Tripaldi, R., Castelnuovo, A. F. D., Tartaro, A., Mengozzi, A., Cosentino, F., Cipollone, F., Consoli, A., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02706-8 · Cited by 9 · see citing works
Kozaczek, M., Bottje, W. G., Kong, B. C., Albataineh, D., & Hakkak, R. (2021) · Journal of Medicinal Food · doi:10.1089/jmf.2020.0180 · Cited by 3 · see citing works
The Effect of Tff3 Deficiency on the Liver of Mice Exposed to a High-Fat Diet
Bazina, I., Šešelja, K., Pirman, T., Horvatić, A., Erman, A., Mihalj, M., & Lončar, M. B. (2025) · Biomedicines · doi:10.3390/biomedicines13051024 · Cited by 2 · see citing works
Mao, Y.-J., Ying, M., & Xu, G. (2022) · All Life · doi:10.1080/26895293.2022.2114550 · Cited by 2 · see citing works
Ma, W., Zhong, X., Cai, B., Shao, M., Yu, X., Lv, M., Xu, S., Zhan, B., Li, Q., Ma, M., et al. (2023) · medRxiv · doi:10.1101/2023.10.05.23296635 · Cited by 2 · see citing works
Ma, X., Qi, S., Qi, S., Zhang, J., Zhang, J., Pang, T., Hou, W., & Ma, X. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-02076-3 · Cited by 1 · see citing works
Zhelezniakova, N., & Rozhdestvenska, A. O. (2021) · Maltepe Tıp Dergisi · doi:10.35514/mtd.2021.50 · Cited by 1 · see citing works
Zhelezniakova, N., & Rozhdestvenska, A. O. (2021) · EUREKA Health Sciences · doi:10.21303/2504-5679.2021.001854 · Cited by 1 · see citing works
Elbadr, M. M., Mohamed, E. A., Elsayed, H., & Abdel-Rahman, M. S. (2023) · Bulletin of Pharmaceutical Sciences Assiut · doi:10.21608/bfsa.2023.327568
Sakhr, H. M., Hassan, M. H., Taha, A. M., & Bakri, A. H. (2025) · Korean Journal of Pediatrics · doi:10.3345/cep.2025.00731
Rozhdestvenska, A. O., & Zhelezniakova, N. (2021) · DergiPark (Istanbul University)
Yuan, H., Li, Y., Li, Q., Geng, S., Chen, X., Zhu, Y., & Jiang, H. (2026) · Critical Public Health · doi:10.1080/09581596.2026.2672202
- Authors
- Tilg, H., Effenberger, M., & Adolph, T. E.
- Affiliations
- Innsbruck Medical University (AT)
- Corresponding author
- Tilg, Herbert
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2019-10-24
- Volume
- 29
- Issue
- 2
- Pages
- 103-106
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2980364347
- Cited by
- 28
- References
- 27
- Citations by year
- 2026: 1 · 2025: 7 · 2024: 4 · 2023: 2 · 2022: 4 · 2021: 10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Expert Opinion on Investigational Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- IL-1 inhibitors, non-alcoholic fatty liver disease, interleukin-1 receptor antagonist, cytokines, anti-inflammatory therapy
- MeSH terms
- Animals, Humans, Interleukin-1alpha, Interleukin-1beta, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
